The University of Texas MD Anderson Cancer Center and pharmaceutical giant Pfizer say they’ll jointly evaluate new combinations of three investigational immunotherapies and other agents to treat various solid tumors and blood cancers. The clinical agreement covers five studies, for now. An MD Anderson/Pfizer joint steering committee will oversee the initiative. Pfizer’s investigational therapies to […]